Indication
Bullous pemphigoid
Bullous pemphigoid is a chronic autoimmune subepidermal blistering dermatosis that predominantly affects older adults, typically those over 60 to 70 years of age. Read more about Bullous pemphigoid
3 drugs 1 manufacturers
Drugs that treat it
Common Bullous pemphigoid therapies.
DUPIXENT PEN (dupilumab)
DUPIXENT SYRINGE (dupilumab)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonBullous pemphigoid is a chronic autoimmune subepidermal blistering dermatosis that predominantly affects older adults, typically those over 60 to 70 years of age.
It is primarily mediated by circulating IgG autoantibodies directed against hemidesmosomal structural antigens—specifically BP180 and BP230—at the dermoepidermal junction, which triggers complement activation, inflammatory cell recruitment, and tissue separation.
Clinically, the condition manifests with severe pruritus alongside tense, fluid-filled bullae and erosions arising on normal-appearing, urticarial, or erythematous skin, most commonly involving the flexural extremities and lower abdomen.
Mucosal membrane involvement can occur, though it is usually mild and less prominent than cutaneous disease.
- nih.gov
Bullous pemphigoid is a chronic autoimmune subepidermal blistering dermatosis that predominantly affects older adults, typically those over 60 to 70 years of age It is primarily mediated by circulating IgG autoantibodies directed against hemidesmosomal structural antigens—specifically BP180 and BP230—at the dermoepidermal junction, which triggers complement activation, inflammatory cell recruitment, and tissue separation
- nih.gov
Bullous pemphigoid is a chronic autoimmune subepidermal blistering dermatosis that predominantly affects older adults, typically those over 60 to 70 years of age Clinically, the condition manifests with severe pruritus alongside tense, fluid-filled bullae and erosions arising on normal-appearing, urticarial, or erythematous skin, most commonly involving the flexural extremities and lower abdomen
- nih.gov
It is primarily mediated by circulating IgG autoantibodies directed against hemidesmosomal structural antigens—specifically BP180 and BP230—at the dermoepidermal junction, which triggers complement activation, inflammatory cell recruitment, and tissue separation Mucosal membrane involvement can occur, though it is usually mild and less prominent than cutaneous disease
- nih.gov
It is primarily mediated by circulating IgG autoantibodies directed against hemidesmosomal structural antigens—specifically BP180 and BP230—at the dermoepidermal junction, which triggers complement activation, inflammatory cell recruitment, and tissue separation Clinically, the condition manifests with severe pruritus alongside tense, fluid-filled bullae and erosions arising on normal-appearing, urticarial, or erythematous skin, most commonly involving the flexural extremities and lower abdomen
Personalize your experience
Follow Bullous pemphigoid and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.